Literature DB >> 33542969

Treatment Rechallenge With Checkpoint Inhibition in Patients With Mismatch Repair-Deficient Pancreatic Cancer After Planned Treatment Interruption.

Vaia Florou1, Christopher Nevala-Plagemann1, Kristin E Barber1, Jenna N Mastroianni1, Courtney C Cavalieri1, Ignacio Garrido-Laguna1.   

Abstract

Entities:  

Year:  2020        PMID: 33542969      PMCID: PMC7846057          DOI: 10.1200/PO.20.00052

Source DB:  PubMed          Journal:  JCO Precis Oncol        ISSN: 2473-4284


× No keyword cloud information.
  22 in total

1.  Durable cancer regression off-treatment and effective reinduction therapy with an anti-PD-1 antibody.

Authors:  Evan J Lipson; William H Sharfman; Charles G Drake; Ira Wollner; Janis M Taube; Robert A Anders; Haiying Xu; Sheng Yao; Alice Pons; Lieping Chen; Drew M Pardoll; Julie R Brahmer; Suzanne L Topalian
Journal:  Clin Cancer Res       Date:  2012-11-20       Impact factor: 12.531

2.  Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma.

Authors:  Joaquim Bellmunt; Ronald de Wit; David J Vaughn; Yves Fradet; Jae-Lyun Lee; Lawrence Fong; Nicholas J Vogelzang; Miguel A Climent; Daniel P Petrylak; Toni K Choueiri; Andrea Necchi; Winald Gerritsen; Howard Gurney; David I Quinn; Stéphane Culine; Cora N Sternberg; Yabing Mai; Christian H Poehlein; Rodolfo F Perini; Dean F Bajorin
Journal:  N Engl J Med       Date:  2017-02-17       Impact factor: 91.245

3.  Is it possible to rechallenge with PD-1/PD-L1 inhibitors after progression?

Authors:  Khalil Saleh; Nadine Khalifeh-Saleh; Hampig Raphaël Kourie
Journal:  Immunotherapy       Date:  2018-04       Impact factor: 4.196

4.  Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade.

Authors:  Dung T Le; Jennifer N Durham; Kellie N Smith; Hao Wang; Bjarne R Bartlett; Laveet K Aulakh; Steve Lu; Holly Kemberling; Cara Wilt; Brandon S Luber; Fay Wong; Nilofer S Azad; Agnieszka A Rucki; Dan Laheru; Ross Donehower; Atif Zaheer; George A Fisher; Todd S Crocenzi; James J Lee; Tim F Greten; Austin G Duffy; Kristen K Ciombor; Aleksandra D Eyring; Bao H Lam; Andrew Joe; S Peter Kang; Matthias Holdhoff; Ludmila Danilova; Leslie Cope; Christian Meyer; Shibin Zhou; Richard M Goldberg; Deborah K Armstrong; Katherine M Bever; Amanda N Fader; Janis Taube; Franck Housseau; David Spetzler; Nianqing Xiao; Drew M Pardoll; Nickolas Papadopoulos; Kenneth W Kinzler; James R Eshleman; Bert Vogelstein; Robert A Anders; Luis A Diaz
Journal:  Science       Date:  2017-06-08       Impact factor: 47.728

5.  Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study.

Authors:  Caroline Robert; Antoni Ribas; Jacob Schachter; Ana Arance; Jean-Jacques Grob; Laurent Mortier; Adil Daud; Matteo S Carlino; Catriona M McNeil; Michal Lotem; James M G Larkin; Paul Lorigan; Bart Neyns; Christian U Blank; Teresa M Petrella; Omid Hamid; Shu-Chih Su; Clemens Krepler; Nageatte Ibrahim; Georgina V Long
Journal:  Lancet Oncol       Date:  2019-07-22       Impact factor: 41.316

6.  Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair-Deficient Cancer: Results From the Phase II KEYNOTE-158 Study.

Authors:  Aurelien Marabelle; Dung T Le; Paolo A Ascierto; Anna Maria Di Giacomo; Ana De Jesus-Acosta; Jean-Pierre Delord; Ravit Geva; Maya Gottfried; Nicolas Penel; Aaron R Hansen; Sarina A Piha-Paul; Toshihiko Doi; Bo Gao; Hyun Cheol Chung; Jose Lopez-Martin; Yung-Jue Bang; Ronnie Shapira Frommer; Manisha Shah; Razi Ghori; Andrew K Joe; Scott K Pruitt; Luis A Diaz
Journal:  J Clin Oncol       Date:  2019-11-04       Impact factor: 44.544

7.  The effect and safety of immune checkpoint inhibitor rechallenge in non-small cell lung cancer.

Authors:  Hiromi Watanabe; Toshio Kubo; Kiichiro Ninomiya; Kenichiro Kudo; Daisuke Minami; Etsuko Murakami; Nobuaki Ochi; Takashi Ninomiya; Daijiro Harada; Masayuki Yasugi; Eiki Ichihara; Kadoaki Ohashi; Keiichi Fujiwara; Katsuyuki Hotta; Masahiro Tabata; Yoshinobu Maeda; Katsuyuki Kiura
Journal:  Jpn J Clin Oncol       Date:  2019-08-01       Impact factor: 3.019

8.  Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer.

Authors:  Martin Reck; Delvys Rodríguez-Abreu; Andrew G Robinson; Rina Hui; Tibor Csőszi; Andrea Fülöp; Maya Gottfried; Nir Peled; Ali Tafreshi; Sinead Cuffe; Mary O'Brien; Suman Rao; Katsuyuki Hotta; Melanie A Leiby; Gregory M Lubiniecki; Yue Shentu; Reshma Rangwala; Julie R Brahmer
Journal:  N Engl J Med       Date:  2016-10-08       Impact factor: 91.245

9.  Evaluation of Readministration of Immune Checkpoint Inhibitors After Immune-Related Adverse Events in Patients With Cancer.

Authors:  Audrey Simonaggio; Jean Marie Michot; Anne Laure Voisin; Jérome Le Pavec; Michael Collins; Audrey Lallart; Geoffray Cengizalp; Aurore Vozy; Ariane Laparra; Andréa Varga; Antoine Hollebecque; Stéphane Champiat; Aurélien Marabelle; Christophe Massard; Olivier Lambotte
Journal:  JAMA Oncol       Date:  2019-09-01       Impact factor: 31.777

Review 10.  Microsatellite instability and immune checkpoint inhibitors: toward precision medicine against gastrointestinal and hepatobiliary cancers.

Authors:  Yuji Eso; Takahiro Shimizu; Haruhiko Takeda; Atsushi Takai; Hiroyuki Marusawa
Journal:  J Gastroenterol       Date:  2019-09-07       Impact factor: 7.527

View more
  1 in total

Review 1.  Pancreatic Cancer: A Review.

Authors:  Wungki Park; Akhil Chawla; Eileen M O'Reilly
Journal:  JAMA       Date:  2021-09-07       Impact factor: 157.335

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.